Research Analysts’ Weekly Ratings Changes for Apellis Pharmaceuticals (APLS)

Apellis Pharmaceuticals (NASDAQ: APLS) has recently received a number of price target changes and ratings updates:

• 11/13/2025 – Apellis Pharmaceuticals had its “sell (d)” rating reaffirmed by analysts at Weiss Ratings.
• 11/8/2025 – Apellis Pharmaceuticals was upgraded by analysts at Wall Street Zen from a “hold” rating to a “buy” rating.
• 11/6/2025 – Apellis Pharmaceuticals is now covered by analysts at Wolfe Research. They set a “peer perform” rating on the stock.
• 11/5/2025 – Apellis Pharmaceuticals had its price target lowered by analysts at JPMorgan Chase & Co. from $40.00 to $36.00. They now have an “overweight” rating on the stock.
• 11/3/2025 – Apellis Pharmaceuticals had its price target lowered by analysts at Mizuho from $24.00 to $19.00. They now have a “neutral” rating on the stock.
• 10/31/2025 – Apellis Pharmaceuticals had its price target lowered by analysts at Citigroup Inc. from $52.00 to $45.00. They now have a “buy” rating on the stock.
• 10/31/2025 – Apellis Pharmaceuticals had its price target lowered by analysts at TD Cowen from $50.00 to $45.00. They now have a “buy” rating on the stock.
• 10/31/2025 – Apellis Pharmaceuticals had its price target raised by analysts at Robert W. Baird from $50.00 to $52.00. They now have an “outperform” rating on the stock.
• 10/31/2025 – Apellis Pharmaceuticals had its price target lowered by analysts at HC Wainwright from $57.00 to $45.00. They now have a “buy” rating on the stock.
• 10/21/2025 – Apellis Pharmaceuticals had its “buy” rating reaffirmed by analysts at HC Wainwright.
• 10/15/2025 – Apellis Pharmaceuticals is now covered by analysts at Wells Fargo & Company. They set an “overweight” rating and a $32.00 price target on the stock.
• 10/8/2025 – Apellis Pharmaceuticals had its “sell (e+)” rating reaffirmed by analysts at Weiss Ratings.
• 9/27/2025 – Apellis Pharmaceuticals had its “sell (e+)” rating reaffirmed by analysts at Weiss Ratings.
• 9/26/2025 – Apellis Pharmaceuticals was downgraded by analysts at The Goldman Sachs Group, Inc. from a “neutral” rating to a “sell” rating. They now have a $18.00 price target on the stock, down previously from $26.00.

Insider Buying and Selling

In other news, General Counsel David O. Watson sold 5,000 shares of the stock in a transaction on Monday, November 17th. The stock was sold at an average price of $20.06, for a total value of $100,300.00. Following the sale, the general counsel directly owned 108,730 shares of the company’s stock, valued at approximately $2,181,123.80. This represents a 4.40% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. Also, CFO Timothy Eugene Sullivan sold 10,000 shares of the firm’s stock in a transaction on Tuesday, October 21st. The shares were sold at an average price of $28.03, for a total value of $280,300.00. Following the transaction, the chief financial officer owned 110,936 shares of the company’s stock, valued at $3,109,536.08. The trade was a 8.27% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Insiders have sold a total of 312,921 shares of company stock worth $8,452,166 over the last three months. 6.80% of the stock is owned by corporate insiders.

Apellis Pharmaceuticals, Inc, a commercial-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutic compounds through the inhibition of the complement system for autoimmune and inflammatory diseases. It offers EMPAVELI for the treatment of paroxysmal nocturnal hemoglobinuria, C3 glomerulopathy and immune complex membranoproliferative glomerulonephritis, and hematopoietic stem cell transplantation-associated thrombotic microangiopathy; and SYFOVRE for treating geographic atrophy secondary to age-related macular degeneration and geographic atrophy (GA).